Mr. Nils Behrndt, Deputy Head of Unit, Directorate F2 (Pharmaceuticals), DG Enterprise and Industry, European Commission has agreed to join the TOPRA Advisory Council.
TOPRA received yet another endorsement of its leading role in the global regulatory affairs industry. Mr. Nils Behrndt, Deputy Head of Unit, Directorate F2 (Pharmaceuticals), DG Enterprise and Industry, European Commission has agreed to join the TOPRA Advisory Council.
Mr. Behrndt has enjoyed an illustrious career at the European Commission, previously serving as the Acting Head of the Directorate F2. Mr. Behrndt has served the Commission since 2000 as a lawyer and advisor. Previously, he served as a lawyer and researcher for a variety of organisations and entities within Germany. He holds law degrees from Germany and the United Kingdom as well as having a Ph.D. in public administration and law.
TOPRA's President, Margareth Jorvid said, "We are delighted that Nils has joined our ranks. TOPRA will benefit immensely from his guidance and technical expertise offered through our Advisory Council."
Ms. Jorvid went onto say, "I think that this appointment really shows the maturity of our organisation and our expanding appeal worldwide, but most especially within the European Union. We are proud to have such a high-ranking official from the European Commission join TOPRA's Advisory Council."
TOPRA members are currently drawn from 52 countries.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.